Join our community of smart investors

Imperial Brands takes advantage of its pricing power

It's also appealing a decision by the US Food and Drug Administration that's holding back sales
May 16, 2023
  • Price rises mitigate volume declines
  • US new product sales hit by FDA decision

Imperial Brands (IMB) saw a continuation of volume declines at the half-year mark. This was partly the result of the tobacco group’s exit from Russia following the invasion of Ukraine. But it’s really part of a secular trend in the industry, at least in terms of its traditional product range.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in